Sector Chart COMPASS Pathways plc

Stocks

CMPS

US20451W1018

Biotechnology & Medical Research

Market Closed - Nasdaq 01:00:00 11/11/2026 +04			5-day change	1st Jan Change
9.250 ^USD	+0.76%		+7.68%	+34.06%

11-09	Compass Pathways Submits NDA for COMP360 Psilocybin to FDA for Treatment-Resistant Depression	MT
11-09	Compass Pathways plc Completes Submission of New Drug Application to U.S. FDA for Comp360 Psilocybin for Treatment-Resistant Depression	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes